#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16462	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2070	789.5	0	.	n	.	0	C451T	SNP	451	451	C	676	676	T	992	T,C	476,429	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16462	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2070	789.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1409	1409	C	946	C	856	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30258	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3680	820.2	0	.	n	.	0	T695C	SNP	695	695	T	1087	1087	C	903	C	822	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30258	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3680	820.2	0	.	n	.	0	A1638G	SNP	1638	1638	A	2030	2030	G	974	G,A	652,237	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30258	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3680	820.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2363	2363	C	996	C,T	887,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30258	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3680	820.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2437	2437	A	993	A	919	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30258	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3680	820.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	2989	2989	C	907	C	837	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2284	folP	855	855	100.0	folP.l15.c17.ctg.1	1403	161.3	1	SNP	p	R229S	1	.	.	685	687	AGC	950	952	AGC	243;246;247	A;G;C	219;221;223	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5934	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3381	175.0	1	SNP	p	S91F	1	.	.	271	273	TTC	623	625	TTC	187;188;188	T;T;C	168;168;159	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5934	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3381	175.0	1	SNP	p	D95G	1	.	.	283	285	GGC	635	637	GGC	182;183;179	G,T;G;C	162,1;165;157	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5934	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3381	175.0	1	SNP	p	G95N	0	.	.	283	285	GGC	635	637	GGC	182;183;179	G,T;G;C	162,1;165;157	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1740	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1374	126.3	1	SNP	p	G45D	0	.	.	133	135	GGC	474	476	GGC	210;210;213	G;G,T;C	192;193,1;195	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	860	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1061	80.4	0	.	n	.	0	A197.	DEL	197	197	A	495	495	A	217	A	199	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5804	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2906	198.9	1	SNP	p	D86N	0	.	.	256	258	GAC	592	594	GAC	220;222;226	G;A;C	201;199;210	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5804	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2906	198.9	1	SNP	p	R87W	0	.	.	259	261	CGT	595	597	CGT	223;226;227	C;G;T	206;209;208	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5804	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2906	198.9	1	SNP	p	R87I	0	.	.	259	261	CGT	595	597	CGT	223;226;227	C;G;T	206;209;208	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5804	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2906	198.9	1	SNP	p	S87R	1	.	.	259	261	CGT	595	597	CGT	223;226;227	C;G;T	206;209;208	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5804	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2906	198.9	1	SNP	p	S88P	0	.	.	262	264	TCC	598	600	TCC	226;227;229	T;C;C	208;208;208	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4794	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2608	182.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1503	1505	GGC	249;247;246	G;G;C	226;219;221	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2571	178.0	1	SNP	p	A311V	0	.	.	931	933	GCC	1367	1369	GCC	275;275;275	G;C;C	242;245;245	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2571	178.0	1	SNP	p	I312M	1	.	.	934	936	ATG	1370	1372	ATG	278;277;274	A;T;G	249;248;245	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2571	178.0	1	SNP	p	T316P	0	.	.	946	948	ACC	1382	1384	ACC	256;253;256	A;C;C	230;230;234	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2571	178.0	1	SNP	p	V316T	1	.	.	946	948	ACC	1382	1384	ACC	256;253;256	A;C;C	230;230;234	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2571	178.0	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1883	1885	ACC	259;260;258	A;C;C	223;231;232	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2571	178.0	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1937	1939	GCG	249;251;247	G;C;G	224;227;221	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2571	178.0	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1937	1939	GCG	249;251;247	G;C;G	224;227;221	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2571	178.0	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2060	2062	GGT	217;214;212	G;G;T	191;191;188	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2571	178.0	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2069	2071	AGC	190;191;192	A;G;C	170;169;169	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4588	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2571	178.0	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2087	2089	CCG	161;163;162	C,G;C,G;G,T	124,8;128,1;124,1	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6528	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3087	210.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1625	1627	CCG	233;237;235	C;C;G	208;212;207	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2364	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1692	138.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	491	491	C	160	C	140	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	340	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	413	29.7	0	.	p	.	0	A251V	NONSYN	751	753	GCG	40	42	GTA	45;45;45	G;T;A	35;35;35	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	340	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	413	29.7	0	.	p	.	0	S271T	NONSYN	811	813	TCG	100	102	ACT	75;71;69	A;C;T	66;62;61	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	340	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	413	29.7	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	106	108	GAT	60;59;54	G;A;T	53;53;48	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	340	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	413	29.7	0	.	p	.	0	D276N	NONSYN	826	828	GAT	115	117	AAC	55;55;55	A;A;C	49;48;48	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	340	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	413	29.7	0	.	p	.	0	N277H	NONSYN	829	831	AAC	118	120	CAC	56;56;56	C;A;C	47;47;49	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	340	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	413	29.7	0	.	p	.	0	R307E	NONSYN	919	921	AGA	208	210	GAA	21;21;21	G;A;A	21;21;21	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	340	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	413	29.7	0	.	p	.	0	T311A	NONSYN	931	933	ACA	220	222	GCA	20;19;18	G;C;A	20;19;18	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	340	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	413	29.7	0	.	p	.	0	E312D	NONSYN	934	936	GAA	223	225	GAC	18;18;18	G;A;C	18;18;18	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	340	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	413	29.7	0	.	p	.	0	F314I	NONSYN	940	942	TTC	229	231	ATC	17;17;17	A;T;C	17;17;17	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	340	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	413	29.7	0	.	p	.	0	A316S	NONSYN	946	948	GCG	235	237	TCG	17;17;16	T;C;G	17;17;16	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	340	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	413	29.7	0	.	p	.	0	V318A	NONSYN	952	954	GTC	241	243	GCC	15;15;14	G;C;C	15;15;14	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	340	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	413	29.7	0	.	p	.	0	G319S	NONSYN	955	957	GGC	244	246	AGC	14;14;14	A;G;C	14;14;14	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	340	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	413	29.7	0	.	p	.	0	G320A	NONSYN	958	960	GGT	247	249	GCC	14;14;14	G;C;C	14;14;14	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	340	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	413	29.7	0	.	p	.	0	G322V	NONSYN	964	966	GGT	253	255	GTT	13;13;13	G;T;T	13;13;13	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3282	porB1b	1038	1038	99.71	porB1b.l15.c17.ctg.1	1336	240.8	0	.	p	.	0	G210R	NONSYN	628	630	GGA	781	783	AGA	256;256;255	A;G;A,T	233;229;229,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3282	porB1b	1038	1038	99.71	porB1b.l15.c17.ctg.1	1336	240.8	0	.	p	.	0	S217G	NONSYN	649	651	AGT	802	804	GGT	257;259;258	G;G;T	237;238;238	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3282	porB1b	1038	1038	99.71	porB1b.l15.c17.ctg.1	1336	240.8	0	.	p	.	0	G252E	NONSYN	754	756	GGA	907	909	GAA	252;254;252	G;A,G;A	233;235,1;234	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3282	porB1b	1038	1038	99.71	porB1b.l15.c17.ctg.1	1336	240.8	1	SNP	p	G120K	1	.	.	358	360	AAG	511	513	AAG	289;288;288	A;A;G	253;255;246	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3282	porB1b	1038	1038	99.71	porB1b.l15.c17.ctg.1	1336	240.8	1	SNP	p	N121D	0	.	.	361	363	AAC	514	516	AAC	287;280;279	A,C;A;C	252,1;249;247	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3282	porB1b	1038	1038	99.71	porB1b.l15.c17.ctg.1	1336	240.8	1	SNP	p	A121N	1	.	.	361	363	AAC	514	516	AAC	287;280;279	A,C;A;C	252,1;249;247	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11978	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4973	240.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1252	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1119	111.1	1	SNP	p	V57M	1	.	.	169	171	ATG	531	533	ATG	257;258;262	A;T;G	235;232;237	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
